Sign in

Amali Samarasinghe

@amali92.bsky.social
147 followers 376 following 6 posts

🫘 Nephrology/General Medicine Australian🇦🇺| MBBS, FRACP, MHPEd 🎓 Vancouver, UBC Nephrology Fellow Alumni🇨🇦

PostsRepliesMedia
Reposted by Amali Samarasinghe
ISNkidneycare @theisn.org · 17/08/2026
🦓 Recognizing rare kidney diseases starts with the right resources. The ISN Rare Kidney Diseases Toolkit features practical, expert-developed materials, including the ADPKD infographic covering diagnosis, disease progression, and management. 🔗 bit.ly/4pGTNJM #ADPKD #Nephrology
022
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 18/07/2026
Excellent read from @iwashyna.bsky.social voices.nejm.org/doi/full/10.... I still struggle with this, as a PGY29 #MedSky
At a less acute level, Alice was struggling with the question of how much of the scut work she should do and how much to delegate to the intern. When was doing the scut work giving her intern time to think and learn? And when was it interfering with the intern’s learning by depriving them of their experience? In other words, when is sitting back and letting someone else do the tedious work of hospital care “growth,” and when is it “exploitation”?
Even more poignantly, Alice was asking how much she should let her trainees do things differently than she would. The interns are, after all, doctors. Surely they can organize their notes in their own way.
2155
Reposted by Amali Samarasinghe
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 05/06/2026
FIND-CKD: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months ca. 2026 from @nejm.org #Nephpearls #ERA26 #NephSky 👉 www.nejm.org/doi/full/10....
084
Reposted by Amali Samarasinghe
ASN Publications @asnpublications.bsky.social · 05/06/2026
New research in #ASNJASN shows that, for many women with ADPKD, pregnancy does not accelerate kidney disease progression, helping reduce uncertainty, improve counseling, and support informed family planning decisions. twp.ai/9OW2h6
042
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/03/2026
Finally, FINEONE shows Finerenone reduces albuminuria in T1DM www.nejm.org/doi/full/10.... @nejm.org #NephSKy
figure of albuminuria reduction with finerenone
13113
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 19/02/2026
Very practical UK Kidney Association guidelines for management of BP in Dialysis www.kireports.org/article/S246... KI Reports
UKKA BP in dialysis visual abstract
1104
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 18/02/2026
Australian guidelines on stone prevention in KI Reports www.kireports.org/article/S246... What do you think @weddelite.bsky.social?
Stone prevention algorithm for most and Ca stones Stone prevention algorithm for uric acid and cystineStone prevention algorithm for most and Ca stones
183
Reposted by Amali Samarasinghe
ABC News Bot (unofficial) @abcnewsbot.bsky.social · 14/02/2026
Kimberley resident David Lawford had to wait in Perth until someone in his hometown died before he could get access to dialysis on his return.
abc.net.au
Kidney patient forced to wait for someone to die to be able go home
Kimberley resident David Lawford had to wait in Perth until someone in his hometown died before he could get access to dialysis on his return.
055
Reposted by Amali Samarasinghe
Michelle Rheault, MD @rheaultm.bsky.social · 08/02/2026
This is every transplant physician’s nightmare right now.
1105
Amali Samarasinghe @amali92.bsky.social · 06/02/2026
@sstoneman.bsky.social fantastic tables - what a resource 📖
010
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 31/01/2026
The @nejm.org publishes this from the Minnesota Physicians Voices www.nejm.org/doi/full/10....
To the Editor:
As physicians, we took an oath to care for others and to do no harm, promising, in part, “I will remember that I remain a member of society, with special obligations to all my fellow human beings.” The mandate primum non nocere — first, do no harm — has been ingrained in us since medical school.
So here we stand, compelled to share our stories in this moment, so the rest of the country knows what is happening in our state. We are bearing witness to what fear can do to the health of a community.
Regardless of whether we have lived here our whole lives or moved here from the other side of the world, we all call the beautiful state of Minnesota our home. We live in big cities, in suburbs, and in rural areas.
We work in large health systems, in private practices, at academic health centers, in the VA Health Care System, in federally qualified health centers, and with the Indian Health Service. We care for patients throughout our state from birth to death. We teach the next generation of physicians.
In a powerful article in the Journal last spring, Drs. Alice T. Chen and Vivek H. Murthy called on physicians to use their voices to advocate for the health of patients and communities during dangerous times.1
In Minnesota, we have found ourselves in an extraordinarily dangerous time.
As the presence here of Immigration and Customs Enforcement (ICE) has increased, our clinic schedules have filled with missed appointments. Patient volumes have plummeted in our emergency departments (EDs). Each of these missing patients represents a lost opportunity: a chance to intervene, to make a diagnosis, to start or alter treatment, or to turn the tide of chronic illness.
These aren’t patients who don’t care. These are patients who are terrified. When we call to check on them, they tell us they are scared to leave their homes. Scared to drive. Scared to take a bus. Scared that a walk across a parking lot to clinic — a place meant to heal — could put them and their families …We also know the mental health impact of this crisis. Political unrest and the unfair targeting of immigrant communities have deepened fear, grief, and division, and we see the emotional toll every day. Patients are presenting with symptoms of post-traumatic stress disorder, with suicide attempts. We sit with people whose loved ones have been detained, families fractured, and communities shaken by uncertainty and loss. Our hearts break for all of them. These are not abstract issues in a news cycle — they are human lives, families, and communities hurting in very real ways. Holding space for this pain has reminded us that suffering affects us all. Fear, grief, and exhaustion cross political and cultural lines.
We are not immune simply because we are physicians. Dread, desperation, and isolation tighten their grip day by day. We are devastated to witness a beloved nurse colleague, Alex Pretti, gunned down by federal agents. Some of us step out of our homes to provide care for the people of Minnesota knowing that today might be the day when the amount of melanin in our skin outweighs the degrees we have earned and the people we have healed.
And yet we push forward, doing what we can.
We make calls to patients, attempting to manage what we can from afar. But too often the calls go unanswered. Are our patients afraid to pick up? Or are they unable?
We make covert home visits, organize emergency hotlines. We deliver medications, food, and diapers to those who cannot safely leave their homes. When patients do come to see us, we ensure that they leave with enough medication to (we hope) survive this crisis.
We are trained to respond to emergencies. We are trained to go above and beyond in moments of crisis. Whether that means working longer hours tending to the sick or linking arms with vulnerable colleagues to walk them to their cars, we help however we can.
Nevertheless, we struggle against feelings of helplessness, especially when we are not allowed to help. We read the …
0113
Reposted by Amali Samarasinghe
Michelle Rheault, MD @rheaultm.bsky.social · 23/12/2025
New out today: Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial Genetic FSGS CAN be treated. journals.lww.com/cjasn/abstra...
21910
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 07/11/2025
a conservative dialysis strategy in possibly recovering AKI helps people recover faster! jamanetwork.com/journals/jam... in @jama.com from #KidneyWk Like STARRT-AKi et al, at the other end? Small trial - needs replication or this is common sense?
jamanetwork.com
A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury
This trial examines whether a conservative dialysis strategy can improve recovery of kidney function for patients with acute kidney injury who require dialysis.
194
Reposted by Amali Samarasinghe
Nayan Arora @captainchloride.bsky.social · 07/11/2025
We are 2 for 2 with positive trials so far. LIBERATE-D shows benefit with a conservative vs conventional dialysis strategy in AKI-D. The difference in mortality is concerning though? Simultaneous pub 👇🏾 #kidneywk jamanetwork.com/journals/jam...
064
Reposted by Amali Samarasinghe
Jeremy Berg @jeremymberg.bsky.social · 06/11/2025
Nature Reviews Nephrology comment on the harms of NIH grant terminations related to kidney disease www.nature.com/articles/s41...
06528
Amali Samarasinghe @amali92.bsky.social · 06/11/2025
⚠️Trial exclusions of pregnant & child-bearing age women🤰an ongoing challenge 🙏 Dr Vesna Garovic highlighting this #KidneyWk @asnkidney.bsky.social
031
Reposted by Amali Samarasinghe
JAMA @jama.com · 05/11/2025
The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease recommends using equations that include both creatinine and cystatin C for more accurate GFR estimation and risk assessment in CKD. ja.ma/43QS5vy
JAMA Clinical Guidelines Synopsis: Classification and Risk Assessment of Chronic Kidney Disease. Guideline Title: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
076
Reposted by Amali Samarasinghe
Michelle Rheault, MD @rheaultm.bsky.social · 06/11/2025
I like to lump patients with type IV collagen variants into 4 main categories that can help predict risk of progression and recommended treatment. #KidneyWk
164
Amali Samarasinghe @amali92.bsky.social · 05/11/2025
Fantastic Day 1 ✅ #KidneyWk @asnkidney.bsky.social
021
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/11/2025
watch out - ORIGIN-3 and FINEONE likely simultaneous publications tomorrow morning! #KidneyWk
1146
Reposted by Amali Samarasinghe
Michelle Rheault, MD @rheaultm.bsky.social · 05/11/2025
Ben Wooden kicks off the #KidneyWk Glomerular Disease conference showing the explosion of discovery of glomerular disease genes since 1990. pubmed.ncbi.nlm.nih.gov/32205319/
172
Amali Samarasinghe @amali92.bsky.social · 04/11/2025
Time for my first ASN 👩‍🏫 @asnkidney.bsky.social
060
Reposted by Amali Samarasinghe
Nephrology Times @nephtimes.bsky.social · 19/09/2025
A review revealed which #CKD drugs are safe to use while #breastfeeding but evidence for many therapies is still lacking. #kidneydisease #nephrology #nephsky docwirenews.com/post/review-...
docwirenews.com
Review of CKD Drug Safety With Breastfeeding | Docwire News
A review revealed which drugs commonly used in chronic kidney disease (CKD) have been found safe to use while breastfeeding. However, evidence for many therapies is still lacking.
041
Reposted by Amali Samarasinghe
Boback Ziaeian @boback.bsky.social · 26/08/2025
Going to add this to my lecture slides.
02915
Reposted by Amali Samarasinghe
Joel Topf @kidneyboy.bsky.social · 18/09/2025
GLP1ra in ADPKD? pubmed.ncbi.nlm.nih.gov/40815122/
pubmed.ncbi.nlm.nih.gov
GLP-1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis - PubMed
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that is caused by mutations in PKD genes. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medicati...
3147
Reposted by Amali Samarasinghe
Nephrology Journal Club @nephjc.bsky.social · 17/09/2025
T1b BP Measurement: In 2017 ‘proper’ technique was recommended and that has transitioned to standardized technique in 2025. Let’s all use a checklist…and let’s use it every time! How close is your regular practice to this standard? #NephJC
4102
Reposted by Amali Samarasinghe
ASN Publications @asnpublications.bsky.social · 18/07/2025
Use of genetics for kidney disease research reveals an array of variants in COL4A genes and a resulting range of disease presentations. From hematuria to Alport syndrome, genetic data has provided a new basic research basis for genotype-phenotype correlations. kidney.pub/KN1707-08 #ASNKidneyNews
082
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 28/06/2025
Poignant cartoon on therapeutics (here vaccines) in pregnancy absolutelymaybe.plos.org/2025/06/27/d... Renalism is a similar issue! From @hildabast.bsky.social
Cartoon
0131
Reposted by Amali Samarasinghe
Rolando Claure @runningkidneys.bsky.social · 21/05/2025
Cystatin C vs. Creatinine in AKI recovery eGFRcr may overestimate kidney function post-AKI due to muscle loss. A KI Reports study found eGFRcys was lower, flagged more CKD, and a higher creatinine–cystatin C index (CMI) predicted lower 5-year mortality. www.kireports.org/article/S246...
021
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 20/05/2025
Promising! flozination in ADPKD (mostly older adults with DM or CVD) - presumably those with another valid indication - associated with slower GFR slope journals.lww.com/cjasn/pages/... in @asnpublications.bsky.social #CJASN With no obvious harm signal
journals.lww.com
Sodium-Glucose Cotransporter-2 Inhibitor Therapy and... : Clinical Journal of the American Society of Nephrology
study within the Veterans Health Administration included adults with an ADPKD diagnosis code who initiated SGLT2i between January 2017 and May 2023. Repeated measures models were used to evaluate eGFR...
1148
Reposted by Amali Samarasinghe
Madhu Pai, MD, PhD @madhupai.bsky.social · 15/05/2025
We’re making measles great again 😡😡😡
25117
Reposted by Amali Samarasinghe
Nephrology Journal Club @nephjc.bsky.social · 15/04/2025
Hey #NephSky and #MedSky Check out the VA for our discussion 4/15/25 at 9pm EST Metformin-Should I Stay or Should I Go (in patients with advanced CKD) VA by @nephroseeker.medsky.social www.nephjc.com/news/metformin-ckd-va
nephjc.com
Metformin in Advanced CKD — NephJC
Should we continue metformin in eGFR under 30 ml/min? The visual abstract by Cristina Popa summarizes the conclusions from the Scottish cohort using target trial methodology.
01311
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 10/04/2025
Interesting study of sleep duration by using Fitbit trackers in hemodialysis From the Renal Research Institute in @asnpublications.bsky.social K360 journals.lww.com/kidney360/pa... 1/ #NephSky
journals.lww.com
Dialysis-Imposed Patterns of Nocturnal Sleep Duration: A... : Kidney360
nal study, patients on in-center hemodialysis were equipped with activity trackers (Fitbit® Charge 2™). Nocturnal sleep duration was assessed according to dialysis start time (early starters: before 8...
1103
Amali Samarasinghe @amali92.bsky.social · 06/04/2025
Spring has sprung - Vancouver
020
Reposted by Amali Samarasinghe
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 03/04/2025
Venous Thromboembolism Prevention in Nephrotic Syndrome: The Role of Aspirin, Vitamin K Antagonists, and Direct Oral Anticoagulants ca. 2025 from @kireports.bsky.social @saynanorouzi.bsky.social @kdjhaveri.bsky.social #Nephpearls #NephSky 👉 www.kireports.org/article/S246...
383
Reposted by Amali Samarasinghe
ASN Publications @asnpublications.bsky.social · 02/04/2025
Daily monitoring of sCys in patients at risk of AKI would facilitate timely detection and potentially improve clinical outcomes. Future research should focus on validating sCys diagnostic criteria and integrating it with other biomarkers to enhance AKI management. bit.ly/CJASN0654 #ASNCJASN
062
Reposted by Amali Samarasinghe
Josh Waitzman @jwaitz.bsky.social · 02/04/2025
Even if CONVINCE had lower enrollment than planned and a healthier cohort than average ESKD patient, name another 1000+ person RCT that shows a mortality benefit for people on HD. #nephmadness
media.tenor.com
Don'T Worry, I'Ll Wait - Worry GIF
ALT: Don'T Worry, I'Ll Wait - Worry GIF
175
Reposted by Amali Samarasinghe
Ankur Gupta @parthankur.bsky.social · 22/03/2025
B-blockers are now first line antihypertensives in haemodialysis population while ACEI hold the ground in peritoneal dialysis individuals #UKKidney www.ukkidney.org/sites/defaul...
ukkidney.org
162
Reposted by Amali Samarasinghe
UK Kidney Association @ukkidney.org · 23/03/2025
🚨NEW MAJOR GUIDELINE!🚨 We have released a key guideline on managing blood pressure in patients on dialysis One of the first of its kind, this unique & comprehensive guideline makes important recommendations for BP targets, treatment & care strategies. ➡️Download now: ow.ly/pABq50ViWCB
043
Reposted by Amali Samarasinghe
Brian Rifkin @brianrifkin.bsky.social · 20/03/2025
Want to read more about CKM syndrome, that ASN/AHA are trying to move the needle on mortality with integrated patient care. Excellent readable summary from KI reports community. #NephSky www.kireportscommunity.org/post/ckm-syn...
kireportscommunity.org
CKM Syndrome: Finally recognizing the connection between the heart, kidney & metabolic syndrome
The concept of Cardiovascular-Kidney-Metabolic (CKM) syndrome highlights the intricate interplay between cardiovascular, kidney, and metabol
0128
Reposted by Amali Samarasinghe
Sarah Melville @sarahkmels.medsky.network · 12/03/2025
Convenient @kdigo.org series of quick summary videos here too: www.youtube.com/watch?v=KSpZ... Interesting that #flozins are_not_recommended for ADPKD, & I like the emphasis on ABPM &/or home BP monitoring, 👀🤓😀
youtube.com
KDIGO ADPKD Guideline Key Takeaways - Nomenclature, Diagnosis, Prognosis, and Prevalence
YouTube video by KDIGO
053
Reposted by Amali Samarasinghe
Nephrology Times @nephtimes.bsky.social · 19/03/2025
🦴 A study compared #cardiovascular risks and #fracture prevention benefits of denosumab versus oral bisphosphonates in patients on #dialysis. #nephrology #nephsky
docwirenews.com
Cardiovascular Safety, Efficacy of Denosumab Versus Oral Bisphosphonates in Patients on Dialysis | Docwire News
A study compared the risk for cardiovascular events and fracture prevention benefits of denosumab versus oral bisphosphonates among dialysis-dependent patients.
031
Amali Samarasinghe @amali92.bsky.social · 19/03/2025
🙈 not what we want to see
000
Reposted by Amali Samarasinghe
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 16/03/2025
Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review ca. 2025 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/40063723/
0172
Reposted by Amali Samarasinghe
Brian Rifkin @brianrifkin.bsky.social · 15/03/2025
#NephSky #MedSky We support our Nephrology colleagues everywhere! This is not acceptable, free Dr. Alawieh.
11713
Reposted by Amali Samarasinghe
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 14/03/2025
What does a green PD fluid effluent bag mean? This and more in this RFN blog piece www.renalfellow.org/2025/03/12/d... By @drcoolbeans.bsky.social #NephSky
renalfellow.org
The Different Colors Of Peritoneal Dialysate
During a night call in my first year of nephrology fellowship, I was asked a question that I had never heard before: ‘What do I do when I see black effluent d
1207